P
Paul J. Orchard
Researcher at University of Minnesota
Publications - 259
Citations - 14759
Paul J. Orchard is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 48, co-authored 229 publications receiving 12985 citations. Previous affiliations of Paul J. Orchard include University of Pennsylvania.
Papers
More filters
Hematopoietic stem cell transplantation for metabolic storage diseases
TL;DR: The study of transplantation has shown that the transfer of relatively few cells can lead to the development of a fully functional lympho-hematopoietic system in the recipient, that bidirectional immunologic tolerance between post-natal tissues is possible, and that cancer can be eradicated by immunologic means.
Journal ArticleDOI
Interleukin-2 secretion by transduced and unselected BDL-2 lymphoma results in increased survival in mice with previously established disseminated disease.
TL;DR: Evidence is provided that transduction of tumor with MFG based vectors without in vitro selection leads to expression of high levels of IL-2 and can impact the survival of animals with disseminated tumor.
Journal ArticleDOI
Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI.
Natalie E. Taylor,Donald R. Dengel,Troy C. Lund,Kyle Rudser,Paul J. Orchard,Julia Steinberger,Chester B. Whitley,Lynda E. Polgreen +7 more
TL;DR: The results of this study suggest that decrements in skeletal muscle strength depend on MPS diagnosis and severity of disease.
Journal ArticleDOI
Intravenous and Intrathecal Enzyme Replacement Before and After Hematopoietic Cell Transplantation for Hurler Syndrome
Journal ArticleDOI
High-Exposure, Targeted Daily Busulfan and Fludarabine-Based Conditioning for Children Undergoing Hematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders: Outcomes at a Single Center
Weston P. Miller,Melisa K. Stricherz,Cathryn Jennissen,Nicole Sando,Jennifer Danielson,Troy C. Lund,Paul J. Orchard +6 more
TL;DR: The Utrecht group reported highly favorable outcomes following a high-dose busulfan and fludarabine-based preparative regimen in patients with a variety of diagnoses, particularly in comparison to historical regimens that employ two or more alkylating agents.